Celyad Oncology Reports Full Year 2020 Financial Results and Recent Business Highlights
24 mars 2021 16h01 HE
|
Celyad Oncology SA
No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for...
Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call
18 mars 2021 02h00 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, March 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces March 2021 Conference Schedule
01 mars 2021 16h01 HE
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, March 01, 2021 (GLOBE NEWSWIRE) -- Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the...
Celyad Oncology Announces February 2021 Conference Schedule
02 févr. 2021 01h00 HE
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)
20 janv. 2021 16h05 HE
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium
18 janv. 2021 01h00 HE
|
Celyad Oncology SE
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively Tumor burden decrease observed in eight of 15...
Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
11 janv. 2021 16h01 HE
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces Equity Purchase Agreement for up to $40 Million with Lincoln Park Capital
07 janv. 2021 01h00 HE
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...
Celyad Oncology Announces January 2021 Conference Schedule
05 janv. 2021 01h00 HE
|
Celyad Oncology SE
MONT-SAINT-GUIBERT, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC
15 déc. 2020 16h01 HE
|
Celyad SA
Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a...